Integra LifeSciences (IART) Stock Sees Fair Value Cut After Analyst Target Reductions
Published . Updated .
The updated analyst fair value estimate for Integra LifeSciences Holdings has shifted from US$18.38 to US$16.44, which points to a roughly 11% cut in where models now anchor the stock’s longer term potential. This reset lines up with a cluster of lower price targets and mostly
Directly affected
- IART Integra Lifesciences Holdings-11.4%
Named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| IARTNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Integra LifeSciences (IART) Stock Sees Fair Value Cut After Analyst Target Reductions Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| GLD | three days earlier | +3.37% | final price |
| GLD | five days earlier | +3.56% | final price |
| QQQ | three days earlier | +2.99% | final price |
| QQQ | five days earlier | +2.00% | final price |
| SPY | three days earlier | +1.75% | final price |
| SPY | five days earlier | +0.89% | final price |
| TLT | three days earlier | -1.35% | final price |
| TLT | five days earlier | -2.31% | final price |
This story
12 out of 100
“Integra LifeSciences (IART) Stock Sees Fair Value Cut After Analyst Target Reductions” scores 12 out of 100. The score uses 1 sources.